Kymera Therapeutics, Inc. 展现出强劲的财务实力。截至2025年12月31日,公司持有的现金储备高达16亿美元。这一充足的资金为其未来的研发和运营提供了坚实保障,预计足以支持公司各项业务推进至2029年。
Kymera Therapeutics, Inc. 展现出强劲的财务实力。截至2025年12月31日,公司持有的现金储备高达16亿美元。这一充足的资金为其未来的研发和运营提供了坚实保障,预计足以支持公司各项业务推进至2029年。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.